An ideal vascular stent would both inhibit in‐stent restenosis (ISR) and promote rapid re‐endothelialization. In the current study, the performance of arsenic trioxide (ATO)‐drug eluting stent (AES) is compared with the bare metal stent, poly‐...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=O75838888
Yinping Zhao ; Ruolin Du ; Tian Zhou ; Dongchuan Yang ; Yuhua Huang ; Yi Wang ; Junli Huang ; Xiaoyi Ma ; Fugui He ; Juhui Qiu ; Guixue Wang
2018년
-
2192-2640
2192-2659
SCOPUS;SCIE
학술저널
n/a-n/a [※수록면이 p5 이하이면, Review, Columns, Editor's Note, Abstract 등일 경우가 있습니다.]
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
An ideal vascular stent would both inhibit in‐stent restenosis (ISR) and promote rapid re‐endothelialization. In the current study, the performance of arsenic trioxide (ATO)‐drug eluting stent (AES) is compared with the bare metal stent, poly‐...
An ideal vascular stent would both inhibit in‐stent restenosis (ISR) and promote rapid re‐endothelialization. In the current study, the performance of arsenic trioxide (ATO)‐drug eluting stent (AES) is compared with the bare metal stent, poly‐lactic‐co‐glycolic acid–coating metal stent, and rapamycin‐drug eluting stent (RES). In vivo AES is shown to prevent neointimal hyperplasia more efficiently than the others when implanted into the carotid arteries of rabbits. Moreover, AES promotes endothelial cells proliferation and re‐endothelialization more quickly than RES. In vitro ATO exposure significantly increases the viability, proliferation, adhesion, and spreading of primary porcine coronary artery endothelial cells (PCAECs), which are critical for endothelialization. However, ATO exposure reduces the viability of porcine coronary artery smooth muscle cells (PCASMCs). The evaluation of mitochondrial morphology, membrane potential, and function demonstrates that ATO at 2 µmol L−1 causes enlargement of the mitochondrion, enhancement of mitochondrial membrane potential, and adenosine triphosphate (ATP) production in PCAECs but not in PCASMCs. Thus, both in vivo and in vitro studies demonstrate that AES is an effective strategy for rapid re‐endothelialization and inhibition of ISR.
Compared to rapamycin drug‐eluting stents (RES), arsenic trioxide drug‐eluting stents (RES) not only effectively prevent neointimal hyperplasia, but also promote re‐endothelialization in vivo, and arsenic trioxide increases primary porcine coronary artery endothelial cells proliferation through regulating mitochondrial function.Overall, these studies demonstrate that AES is an endothelium‐friendly drug‐eluting stent.
Masthead: (Adv. Healthcare Mater. 15/2018)